Human antibodies to Crimean Congo Hemorrhagic Fever Virus
AssigneeVanderbilt University
InventorJames E. Crowe, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing Crimean Congo Hemorrhagic Fever Virus and methods for use thereof.
Claims20
A method of detecting a Crimean Congo Hemorrhagic Fever Virus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antigen binding fragment thereof comprising heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively;
- and
- (b) detecting Crimean Congo Hemorrhagic Fever Virus in said sample by binding of said antibody or antibody fragment to a Crimean Congo Hemorrhagic Fever Virus antigen in said sample.
A method of treating a subject infected with Crimean Congo Hemorrhagic Fever Virus or reducing the likelihood of infection of a subject at risk of contracting Crimean Congo Hemorrhagic Fever Virus, comprising delivering to said subject an antibody or antigen binding fragment thereof comprising heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively.
A monoclonal antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively, wherein said antibody is a recombinant IgG antibody or antibody fragment comprising an Fc portion mutated to eliminate or enhance FcR interactions compared to wild-type, to increase half-life and/or increase therapeutic efficacy compared to wild-type, or glycan modified to eliminate or enhance FcR interactions compared to wild-type.
A hybridoma or engineered cell comprising one or more nucleic acid segments encoding an antibody or antigen binding fragment thereof wherein the antibody or antibody fragment comprises heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively.
A vaccine formulation comprising antibodies or antigen binding fragments thereof comprising heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively, wherein said antibodies are recombinant IgG antibodies or antibody fragments comprising an Fc portion mutated to eliminate or enhance FcR interactions compared to wild-type, to increase half-life and/or increase therapeutic efficacy compared to wild-type, or glycan modified to eliminate or enhance FcR interactions compared to wild-type.
A method of determining the antigenic integrity or correct conformation of a Crimean Congo Hemorrhagic Fever Virus antigen comprising:
- (a) contacting a sample comprising said antigen with an antibody or antigen binding fragment thereof comprising heavy and light chain CDR sequences comprising SEQ ID NOS:
- 330, 331, and 332, and SEQ ID NOS:
- 480, 481 and 482, respectively;
- and
- (b) determining antigenic integrity or correct conformation of said antigen by detectable binding of said antibody or antibody fragment to said antigen.
Dependencies are inferred from the claim text.